EMMA Emmaus Life Sciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 822370 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.1%
TTM net income YoY-19.2%
TTM EPS YoY-8.3%
Revenue 3-yr CAGR-21.0%
Net income 3-yr CAGR—
Margins
Gross margin92.1%
Operating margin24.8%
Net margin-61.9%
FCF margin—
EBITDA margin25.2%
Returns
ROE—
ROA-45.1%
ROIC (approx.)—
Asset turnover0.73x
Leverage & solvency
Liabilities / assets487.1%
Debt / equity—
Current ratio0.06x
Interest coverage0.44x
Cash quality & payout
Operating cash flow / net income-0.22x
Accruals ratio-54.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.89M | $6.32M | $1.98M | $3.85M | $3.38M | $2.82M | $2.41M | $3.29M |
| Cost of revenue | $369,000 | $344,000 | $168,000 | $235,000 | $247,000 | $150,000 | $225,000 | $309,000 |
| Gross profit | $1.52M | $5.97M | $1.81M | $3.62M | $3.13M | $2.67M | $2.18M | $2.98M |
| R&D expense | $58,000 | $116,000 | $40,000 | $31,000 | $50,000 | $56,000 | $176,000 | $137,000 |
| SG&A expense | $1.48M | $1.57M | $1.85M | $1.80M | $1.73M | $2.31M | $2.34M | $2.29M |
| Operating income | -$369,000 | $3.79M | -$823,000 | $886,000 | $695,000 | -$370,000 | -$980,000 | -$557,000 |
| Interest expense | $1.86M | $1.60M | $2.13M | $2.27M | $1.93M | $1.68M | $1.26M | $1.28M |
| Pretax income | -$4.74M | $1.34M | -$3.33M | -$1.94M | -$1.50M | -$1.73M | -$2.33M | -$1.74M |
| Income tax | $4,000 | -$1,000 | $4,000 | $16,000 | $579,000 | -$590,000 | $4,000 | $6,000 |
| Net income | -$4.74M | $1.34M | -$3.33M | -$1.95M | -$2.08M | -$1.14M | -$2.33M | -$1.75M |
| EBITDA | -$355,000 | $3.81M | -$808,000 | $901,000 | $710,000 | -$366,000 | -$975,000 | -$552,000 |
| EPS (basic) | -0.07 | 0.02 | -0.05 | — | -0.03 | -0.02 | -0.04 | — |
| EPS (diluted) | -0.07 | 0.02 | -0.05 | — | -0.03 | -0.02 | -0.04 | — |
| Weighted avg. shares (diluted) | 70.19M | 120.54M | 70.19M | — | 63.87M | 63.87M | 63.87M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $971,000 | $2.81M | $1.07M | $2.13M | $293,000 | $886,000 | $1.33M | $1.39M |
| Receivables | $1.52M | $709,000 | $2.05M | $2.80M | $2.62M | $2.07M | $2.06M | $2.62M |
| Inventory | $1.42M | $1.59M | $1.91M | $1.55M | $1.21M | $1.31M | $1.44M | $1.64M |
| Current assets | $4.68M | $6.00M | $6.00M | $7.75M | $4.79M | $5.01M | $5.65M | $6.77M |
| PP&E, net | $73,000 | $86,000 | $98,000 | $113,000 | $128,000 | $143,000 | $41,000 | $46,000 |
| Total assets | $17.73M | $16.37M | $18.70M | $21.44M | $20.76M | $23.34M | $22.48M | $23.60M |
| Current liabilities | $72.89M | $66.12M | $70.54M | $69.07M | $64.17M | $62.08M | $64.92M | $63.55M |
| Long-term debt | $25.02M | $24.99M | $26.56M | $27.13M | $29.07M | $29.73M | $29.01M | $28.96M |
| Total debt | $25.02M | $24.99M | $26.56M | $27.13M | $29.07M | $29.73M | $29.01M | $28.96M |
| Total liabilities | $86.39M | $82.55M | $86.56M | $85.04M | $80.24M | $79.05M | $81.08M | $80.08M |
| Shareholders' equity | -$68.65M | -$66.18M | -$67.86M | -$63.61M | -$59.49M | -$55.70M | -$58.60M | -$56.48M |
| Net debt | $24.05M | $22.18M | $25.49M | $25.00M | $28.78M | $28.85M | $27.67M | $27.58M |
| Shares outstanding | 70.19M | 70.19M | 70.19M | 70.19M | 63.87M | 63.87M | 63.87M | 63.87M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.67M | $1.69M | -$344,000 | $2.21M | $409,000 | -$2.91M | $279,000 | $343,000 |
| Capital expenditure | $0 | — | — | $0 | $0 | — | — | $6,000 |
| Free cash flow | -$1.67M | — | — | $2.21M | $409,000 | — | — | $337,000 |
| Investing cash flow | -$15,000 | $1.58M | $0 | $0 | $0 | $2.17M | $0 | -$2,000 |
| Financing cash flow | -$168,000 | -$1.53M | -$702,000 | -$362,000 | -$1.00M | $284,000 | -$345,000 | -$195,000 |
| Depreciation & amortization | $14,000 | $14,000 | $15,000 | $15,000 | $15,000 | $4,000 | $5,000 | $5,000 |
| Stock-based compensation | $0 | $0 | $1,000 | $7,000 | $9,000 | -$1,000 | $10,000 | $29,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.